Apogee Therapeutics, Inc. Common Stock Cash Flow Conversion Efficiency
Apogee Therapeutics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Apogee Therapeutics, Inc. Common Stock (APGE) has a cash flow conversion efficiency ratio of -0.060x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-71.38 Million) by net assets ($1.19 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Apogee Therapeutics, Inc. Common Stock (2022–2025)
Cash flow conversion efficiency of Apogee Therapeutics, Inc. Common Stock from 2022 to 2025. This chart illustrates how Apogee Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View APGE live share price for real-time trading data and today's change.
Apogee Therapeutics, Inc. Common Stock Cash Flow Conversion Ratio Explained
Apogee Therapeutics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Apogee Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apogee Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see market cap of Apogee Therapeutics, Inc. Common Stock for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Commercial & Savings Bank Ltd
TW:5876
|
0.029x |
|
Match Group Inc
NASDAQ:MTCH
|
-0.891x |
|
ALIB.HL.INF.TEC.UNSP.ADR
F:TWYA
|
N/A |
|
10X Genomics Inc
NASDAQ:TXG
|
0.021x |
|
Piraeus Financial Holdings S.A
AT:TPEIR
|
0.109x |
|
Quinenco
SN:QUINENCO
|
0.028x |
|
Datang International Power Generation Co Ltd Class A
SHG:601991
|
0.082x |
|
CAE Inc.
TO:CAE
|
0.038x |
Annual Cash Flow Conversion Efficiency for Apogee Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Apogee Therapeutics, Inc. Common Stock from 2022 to 2025. Review APGE FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $903.88 Million | $-227.45 Million | -0.252x | -5.37% |
| 2024-12-31 | $716.79 Million | $-171.17 Million | -0.239x | -21.35% |
| 2023-12-31 | $379.91 Million | $-74.76 Million | -0.197x | -70.20% |
| 2022-12-31 | $142.07 Million | $-16.43 Million | -0.116x | -- |
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chr… Read more